Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040090 · ClinicalTrials.gov registry record · Phase 2
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
A Phase 2 study of Rabies, sponsored by Kamada.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 1
- Study location
NCT02040090: Completed Phase 2 study of Rabies, sponsored by Kamada.
NCT02040090 is a Phase 2 study of Rabies that has completed, run by Kamada. The registered enrollment target is 118 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02040090, a Phase 2 study of Rabies, has completed, sponsored by Kamada.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine.
Conditions Studied
Interventions
- DRUG Active rabies vaccine (US-FDA approved)
Study Locations (1)
Minnesota
- Prism Research Inc - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT02040090 record still lists
NCT02040090 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 1 condition, with Rabies appearing as the primary indexed condition, and to 1 intervention - of which Active rabies vaccine (US-FDA approved) is the first listed.
NCT02040090 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02040090 about?
NCT02040090 is a clinical study titled "Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects". The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as...
What is the current status of trial NCT02040090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2013-04. Estimated completion is 2014-08.
What conditions does trial NCT02040090 study?
This clinical trial studies the following conditions: Rabies.
What interventions are being tested in trial NCT02040090?
The interventions under investigation include: Active rabies vaccine (US-FDA approved) (DRUG).
Who is sponsoring clinical trial NCT02040090?
This trial is sponsored by Kamada, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02040090 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rabies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02040090's enrollment target sits among peer trials
118 618th of 2000 higher than 1,378 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia